Meme Kanserinde ADC Değerleri ile Histopatolojik Prognostik Faktörler Arasındaki İlişkinin Değerlendirilmesi

Relationship Between ADC Values and Histopathological Prognostic Factors in Breast Cancer

Eser Ümmühan MERMİ YETİŞ1*, Rahmi ÇUBUK1*, Ahmet MIDI3*, Levent ÇELİK3*

1Department of Radiology, Maltepe University Faculty of Medicine, Istanbul, Turkey
2Department of Pathology, Bahcesehir University Faculty of Medicine, Istanbul, Turkey
3Department of Radiology, Radiologic Imaging Center, Istanbul, Turkey

ÖZ

GİRİŞ ve AMAÇ: Meme kanserinde difüzyon MR, lezyonun morfolojisi yanında, metabolik aktivitesi hakkında da bilgi vermektedir. Patolojik prognostik faktörler meme kanserli olgularında tedavi protokolünü ve sağ kalımı etkilemektedir. Bu çalışmada amaçımız, meme kanserli olgulara ADC değerleri ile patolojik prognostik faktörler arasındaki ilişkini değerlendirilmişdir.

YÖNTEM ve GERÇELER: Kliniğizmide, meme kanserli tanmış ile preoperatif olarak Meme MR tettikii yapılan 33 olgularda retrospektif olarak değerlendirildi. Seçil 33 olguda toplam 44 malign kitle vardı. Tüm oğlunların post-operatif patoloji sonucu ile elde edildi. Post-op histopatlojik spesmenlerde tümör capı, aksiler lenf nodu durumu, histolojik grade klasik prognostik faktörler olarak ve östrojen reseptör durumu, progesteron reseptör durumu moleküler prognostik faktörler olarak değerlendirilmiştir. Difüzyon meme MR özellikleri ile klasik ve moleküler histopatolojik prognostik faktörler arasındaki ilişki Mann Whitney U test, Kruskal Wallis test ve Spearman korelasyon analizi kullanılarak değerlendirildi.

BULGULAR: ADC değerleri, aksiler lenf nodu tutulumu 3’den az olan oğlularda (N1) aksiler lenf nodu tutulumu 4 ve/veya daha fazla olan oğulara (N2-N3) göre anlamlı düzeyde yüksek bulundu (p=0.011; p=0.010; p<0.05).

TARTIŞMA ve SONUÇ: Sonuç: Düşük ADC değerleri lenf nodu tutulumuya ilişkiliydii.

Anahtar Kelimeler: Difüzyon, Meme Kanser, Manyetik Rezonans Görüntüleme

Abstract

INTRODUCTION: To evaluate the relationship between ADC values and histopathological prognostic factors in breast cancer patients. Materials and Methods A total of 33 female breast cancer patients with preoperative breast MRI image were retrospectively evaluated. There were a total of 44 malignant masses in 33 patients. RESULTS: ADC was significantly lower in patients with 4 and/or more axillary lymph nodes involvement (N2-N3) compared to those with <3 axillary lymph nodes involvement (p=0.011; p=0.010; p<0.05). DISCUSSION and CONCLUSION: Lower ADC values are related with axillary lymph node involvement.

Keywords: Diffusion, Breast Neoplasm, Prognosis

INTRODUCTION

Breast cancer is the most common of the cancer-related mortality in females following the lung cancer (1). Breast cancer is a heterogeneous disease with different molecular properites, biological behaviors, clinical courses and prognosis (1-2). Breast MRI images can give information about morphologic and dynamic properties of the lesion and is usually used for the lesions that could not be evaluated with other imaging methods, in the evaluation of multicentricity and bilaterality, in identifying the recurrent-residual lesions and for differentiation of the lesions such as scar tissue, fat necrosis and granulation tissue (3,4). The use of diffusion MRI in the breast is increasing in recent years,
because it gives information about the morphology as well as microstructural characteristics of the lesion. In malignant lesions, diffusion restriction increases and ADC-value decreases with the increased b-value.

In patients with breast cancer, recent studies have been found in the literature on the relationship between the data obtained from preoperative breast MRI and the prognostic factors determined on postoperative evaluation of pathological specimens. These studies have particularly studied the morphological features on conventional breast MRI and have reported similar results (1,5,6). Although the relationship between the diffusion breast MRI and histopathological prognostic factors was studied in recent years (2,7-11). Some studies have reported that diffusion MRI images can be used to differentiate and to characterize the benign and malign breast lesions and that ADC-values may be associated with prognostic factors (2,7-11).

The purpose of the present study was to evaluate the relationship between ADC values and conventional (tumor size, axillary lymph node involvement, histopathological grade, multifocal disease and lenfovascular invasion) and molecular (estrogen and progesteron receptors, Cerb-B2) prognostic factors for breast cancer.

METHODS

Ethics committee approval was received from the İstanbul Kartal Dr. Lütfi Kirdar Education and Research Hospital Scientific Resarch and Science Board with the decision dated 05.02.2013 and numbered 8951337/1009/123 for the study.

Patients

The consecutive patients with a diagnosis of invasive breast cancer in whom preoperative MRI had been obtained were included in the study. We excluded patients with only in situ tumors in the study. Also in order to avoid any alteration in tumor tissue due to histology or grading, the patients in whom MRI was obtained during/after neoadjuvant chemotherapy were excluded from the study. A total of 33 female breast cancer patients were included in the study. There were a total of 44 malignant masses in 33 patients.

Breast MRI imaging protocol

Breast MR imaging was performed on a 1.5T imager (Intera, Philips Medical Systems, Best, The Netherlands) with a dedicated doublebreast four-channel surface coil and bilateral scans. Before the examination, a needle for intravenous administration of contrast agent was placede in cubital vein. Patient was placed in a comfortable prone position. Transverse T2-weighted fat a cubital vein. Patient was placed in a comfortable prone position. Transverse T2-weighted fat supressed spin echo sequence (TE/TR 110/7548 ms; inversion delay SPAIR 80 ms; flip angle 90°; FOV 380x380mm², acquired voxel size 1.06x1.74x3.0 mm³, reconstructed voxel size 0.94x0x94x3x00 mm³, total acquisition time 242s) was performed before adminstration of contrast material. DWI axial sequence:TR, 8000ms; TE, 82ms; 116x123 matrix; thickness, 4mm; FOV, 32cm; parallel acquisition factor: 2.0; and NEX, 2. DWI was acquired before dynamic sequences, with a spin-echo echoplanar imaging (EPI) sequence in the axial plane. Sensitig diffusion gradients were applied sequentially in the x, y and z directions, with b values of 0, 1000 and 1,500 s/mm². A transverse three-dimensional high-resolution T1-values of 0, 1000 and 1,500 s/ mm². A transverse three-dimensional high resolution high-resolution T1-weighted fast gradient echo fat-suppressed sequence [TE/TR 2.4/4.6 ms; inversion delay spectral presaturation attenuated by inversion recovery (SPAIR) 90ms; flip anle 10°; FOV 360x360 mm²,acquired voxel size 0.9x0.9x2.5 mm³, reconstructed voxel size 0.83x0.83x2.50mm³, total acquisition time 60s] was performed before adminstration of contrast.
agent, followed by repeat performance of this same sequence at 0, 1, 2, 3, 4, 5, and 6 min. After administration of contrast agent, Postcontrast three-dimensional T1-weighted fast gradient echodynamic MR images were acquired after administration of 0.1mmol/kg GD-DTPA (gadolinium diethylene triamine-pentaacetic acid dimeglumine). Contrast medium was injected with a 10s timing delay into the antecubital vein with an 18-20G needle at a flow rate of 2ml/s followed by a flush of 20ml of saline-solution.

**Image Interpretation**

Breast MRI images were evaluated by two radiologist having at least 5 years of experiences in breast MR imaging. The greatest diameter of the tumor was considered for statical analysis. The place of circular ROI (region of interest) was determined by the consensus of two radiologists. A single ROI with 5-10 mm² was manually drawn around the borders of the target lesion on the b=1,000 and 1500s/mm² DWI. Care was taken to avoid apparent necrotic or cystic components by referring to other MRI images [13-19]. We obtained two ADC map (b=1000 and b=1500) and we compared them.

**Pathological examination**

Histopathological evaluation was performed by two pathologists having at least 5 years of experience in breast histopathology. Conventional prognostic factors were determined as tumor size, axillary lymph node involvement, multicentricity, histological and nuclear grades, and lymphovascular invasion. On the other, molecular prognostic factors were ER/PR expression, C-erb-B2.

All areas of the preparation were evaluated in the tumor cell for ER and PR, expression. Only the stained areas limited to the nuclei are considered as positive. The intense, normal-, and weak stained cells were multiplied by 3, 2, and 1 respectively to calculate a total score with a maximum of 300 points. Those with a score of <30 were considered as negative.

Characteristic membranous (Chicken-Wire) staining was considered as positive for C-erb-B2. The cells with no staining or weak staining in <10% of the cells were scored as 0=negative, those with weak staining in >10% cells were 1+(negative), those with weak-moderate staining in >10% cells were 2+(unclear), those with moderate-intense staining in <30% cells were 2+(unclear), and those with moderate-intense staining in >30% cells were 3+ (strongly positive).

Estrogen and progesterone receptors were determined as positive or negative, and C-erb-B2 protein (Her-2/neu) was determined as negative, unclear or strongly positive.

Histological grade was determined by using modified Bloom-Richardson-Elston system which includes the nuclear polymorphism, tubule formation and mitosis parameters. Each parameter was scored from 1 to 3 obtain a total score.

Tubule formation was scored as atubulus formation of >75%(=1), 10-75%(=2) or <10%(=3).

Nucleus size was scored as follows: 1=equal to the normal ductus epithelium, 2=medium-sized, and 3=large nucleus.

Mitosis was scored on 10 bba (X400 magnification, 0.186 mm²:2/3) as a mitosis count of 0-7(=1), 8-14(=2) or >14(=3).

Nuclear grade was determined according to modified Black system as follows: for nuclei diameter, 1=small, 2=medium and 3=large; for nuclei shape, 1=regular and 2=irregular; for pleomorphism, 1=low, 2=medium and 3=high; for nuclues, 1=not distinguished, 2=distinguished a 3=clear. Nuclear grade was grade I for a total score of 4-6, grade II for 7-8 and grade III for 9-11.
Statistical analysis

Statistical analysis was performed by using NCSS (Number Cruncher Statistical System) 2007 & PASS (Power Analysis and Sample Size) 2008 Statistical Software (Utah, USA). In addition to the descriptive statistics (mean, standard deviation, median, frequency and ratio), Mann Whitney U test was used for the two-group comparison of quantitative parameters with no normal distribution. For the comparison of three or more groups with no normal distribution, Kruskal Wallis test was used, followed by Mann Whitney U test to determine the group responsible for the difference. Spearmann correlation analysis was used to evaluate the association between the parameters. Statistical significance set at p<0.01 and p<0.05.

RESULTS

A total of 33 female breast cancer patients who had a preoperative breast MRI image were included in the study. Study patients aged 37-76 years with a mean age of 53 years. There were a total of 44 malignant masses in 33 patients.

Histology Analysis

The pathology report was invasive ductal carcinoma in 40 patients (91%), invasive lobular carcinoma in 3 (6.8%) and ductal carcinoma in situ with an invasive component in 1 (2.2%).

Tumor size ranged from 4 to 50 mm with a mean size of 20.00±10.94 mm. Tumor size was <2cm in 52.3% of the patients (n=23) and 2-5cm in 47.7%(n=21).

Prognostic factors are summarized in Table 1. As a histological grade, there were 7 patients (15.9%) with grade 1, 13 (29.5%) with grade 2, and 24 (54.6%) with grade 3 lesions.

In 23 of the 44 lesion (52.3%), one or more lymph node involvement was found at histoplastic examination. Of the cases, 47.7%(n=21) had no axillary lymph node, 22.7%(n=10) had 1-3, 20.5% (n=9) had 4-9 and 9.1% (n=4) had more than 9 axillary lymph nodes. Lymph node involvement is summarized in Table 1.

In our series, 88.6% of the tumors were (39/44) ER-positive and 68.2% (30/44) were PR-positive. Thirty-two lesions showed negative (0,1+) c-erbB-2 protein findings, and 12 patients showed positive findings (2+,3+). The median percentage of K6-67 expression was 14.0%.

ADC Value Analysis

The mean ADC-1000 value of all malignant lesions was 0.96x10⁻³mm²/s (range 0.58-1.90x10⁻³mm²/s, SD 0.21x10⁻³mm²/s). The mean ADC-1500 value of all malignant lesions was 0.80x10⁻³mm²/s (range 0.51-1.60x10⁻³mm²/s, SD 0.18x10⁻³mm²/s) (Figs.1,2).

There was no significant correlation between the ADC value and conventional prognostic factors of age, tumor size and histologic/nuclear grades. Relation between ADC values and Prognostic Factors are summarized in Table 1. However, there was a statistical difference between axillary lymph node involvement and ADC 1000 and ADC 1500 values (ADC 1000 p=0.017; p<0.05; ADC 1500 p=0.019; p<0.05). Namely, according to the two-group comparisons, there was no significant difference in ADC -1000 and ADC-1500 values between patients with no axillary lymph node involvement compared to those with 1-3 lymph nodes involvement (p<0.05). Although ADC-1000 value in patients with no axillary lymph node involvement was higher compared to those with 4-9 or >9 axillary lymph node involvement, it did not reach statistical significance (ADC 1000 p=0.055; p=0.053; ADC 1500 p=0.063; p=0.075; p>0.05). ADC-1000 and ADC-1500 values in patients with 1-3 axillary lymph node involvement was significantly higher compared to those with 4-9 or >9 axillary involvements (ADC 1000 p=0.011; p=0.010; p<0.05; ADC 1500 p=0.014; p=0.016; p<0.05). There was no significant difference in ADC-1000 and ADC-1500
values between patients with 4-9 axillary involvement and those with >9 axillary involvements (p>0.05).

There was no significant correlation between the ADC value and molecular prognostic factors, including ER, PR, c-erbB-2.

Figure 1. A 50-year-old woman with breast cancer, diagnosed as invasive ductal carcinoma, histological grade 2, ER (-), PR (+), C Erb B2 3 (+). T1 weighted axial contrast enhanced images (a) shows mass with spiculated margins in the right breast. High signal intensity was detected in the right breast on b1000 and b1500 DWI (b, c). The ADC value was found to be 0.91x10⁻³mm²/s on 1000ADC map (d), 0.79x10⁻³mm²/s on 1500ADC map (e).
Figure 2: A 25-year-old woman with breast cancer diagnosed as invasive ductal carcinoma, histological grade 2, ER / PR (+), C Erb B2. T1 weighted axial contrast enhanced and subtraction (3-1) images (a, b) shows mass in the right breast. The ADC value was found to be 1 x10⁻³mm²/s on b1000 ADC map (c), 0. 9x10⁻³mm²/s on b1500ADC map (d).

**DISCUSSION**

Breast cancer is a heterogenous disease characterized by varying molecular features, biological behavior, clinical course and prognosis (1-2). Therefore, it is important to identify the conventional and molecular prognostic factors in these patients in order to determine the appropriate therapy to increase the survival (19-20). There is evidence that the progression of malignant tumours does not depend exclusively on the cancer cells; it is also influenced by the tumour microenvironment. The tumour microenvironment is a complex system that includes tumour cells, stromal cells (such as adipocytes, fibroblasts, endothelial cells, and infiltrating immune cells), and extracellular matrix. Diffusion MR imaging has been shown to have potential in the detection and characterization of breast malignancies, based on its ability to characterize tissue microstructures (3,4,21,22). Microscopic movement is influenced by the molecular diffusion of the water and microcirculation of blood (23,28). On the other hand, diffusion of the water is influenced by cellularity, viscosity, intracellular and extracellular membrane permeability, active transportation, flow and structural arrangement (23,29,30). ADC is a measurable value and many previous studies have showed marked diffusion restriction and lower ADC values in malignant lesions compared to benign lesions (24,25,28,29,31-35). Restricted diffusion and thus lower ADC values are due to high cellularity in cancer tissue, large-nuclei numerous macromolecular protein content and narrowed extracellular distance (27,31).

Many previous studies have showed a significant association between morphological and kinetic properties of the mass lesions on conventional breast MRI and several poor prognostic factors in breast cancer (1,6,36-38). More recent studies have reported that ADC value measured by Diffusion breast MROI is effective in identifying the cancer tissue and the menstruation-related changes in normal breast parenchyme (23). Malignant tumors show lower ADC values compared to benign lesions (23,29,39). In these studies, authors have also investigated the association between ADC value of the cancer tissue and prognostic factors for breast cancer. However, there are conflicting results in the literature about the association between ADC value on diffusion MRI and prognostic factors for...
In our study, there was no significant correlation between the ADC value and conventional prognostic factors, including age, tumor size and histologic/nuclear grades. Another conventional prognostic factor, the axillary lymph node involvement is the most important factors used to predict the prognosis of breast cancer (36). In our study, ADC-1000 and ADC-1500 values were found to be significantly higher in patients with 1-3 axillary lymph node involvement (N1) compared to those with 4-9 (N2) and >10 (N3) axillary lymph node involvement. However, there was no significant difference in ADC-1000 and ADC-1500 values between the patients with no nodal involvement (N0) and N1 patients. Similarly, ADC-1000 and ADC-1500 values did not differ between patients with 4-9 and >9 axillary lymph nodes. According to the TNM staging system regardless of what is T (primary tumor), N2 and N3 patients (4 or more nodal involvement) are classified as stage 3 or more. As a result, lower ADC values found in N2 and N3 patients compared to N0 and N1 patients indicates its association with poor prognostic factors.

Similar to our results, Abdel Razek (9) and Paola Belli et al. (2) have also reported a correlation between low ADC values and positive axillary lymph nodes. On the other hand, in contrast to our results, Takashi Kamitani et al. (10) have found higher ADC values in patients with positive axillary lymph nodes. In the study by Sung Hun Kim et al. (23), ADC values were not correlated with lymph node involvement. This may be due to the fact that authors have included the subgroups of musinous and medullar cancers which are usually associated with high ADC values. It has been already reported that ADC values are higher in mucinous and medullar cancer due to the inflammation associated with higher cellularity (18). There were no patients with musinous or medullar cancer in our study. We included only the patients with invasive ductal and invasive lobular carcinoma as well as in situ carcinomas with an invasive component.

In our study, there was no significant correlation between the ADC value and molecular prognostic factors, including ER, PR, c-erbB-2. Similarly, Sung Hun Kim et al. (23) have found no correlation between ADC value and ER/PR expression. On the other hand, in the studies by Takashi Kamitani et al. (10) Laura Martincich et al. (7) and SY Choi et al. (11), ER expression was correlated with low ADC values. Similar to our study, SY Choi et al. (11), Sung Hun Kim et al. (23) and Takashi Kamitani et al. (10) have also reported no correlation between C-erb-B2 and ADC values. However, Laura Martincich et al. (7) reported a correlation between low ADC values and negative Cerb-B2 values.

Limitations of our study the relative inadequacy in the number of patients as well as lack of a standard b value for diffusion MRI, resulting in conflicting results in previous studies using different b values. Moreover, size of the tumor was <1cm in 7 and <2cm in 24 out of 44 lesions. In small lesions, 3T dW MRI is more effective than 1.5T MRI in identifying a lesion. Because we used 1.5T MRI in our study, the reliability is low for small lesions. On the other hand, Marini et al. (29) have found that ADC values are lower in patients with invasive ductal carcinoma compared to those with other cancer types and we had 3 invasive lobular carcinoma patients in our series. Thus larger and homogeneous patient series are needed for future studies.

In conclusion, ADC value was found to be significantly lower in patients with N2 and N3 disease (axillary lymph node involvement of 4 or more) compared to those with N1 disease (axillary lymph node involvement <3) according to TNM staging system. Despite the lacking the number of the study results of the present study suggest that low ADC value is correlated with lymph node involvement and thus with poor prognosis.

The authors would like to present their thanks to
the radiology technologist Esin Gül, for her technical support.

The Authors declares that there is no conflict of interest.

**Informed Consent:** Written consent was obtained from the participants.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.
Table 1. Relation Between ADC Value and Prograstic Factors

| Factors                        | Number of Lesions (n:44) | ADC 1000     | p         | ADC 1500     | p         |
|--------------------------------|--------------------------|--------------|-----------|--------------|-----------|
|                                |                          | Min-Max/ Mean±SD/Median |           | Min-Max/ Mean±SD/Median |           |
|                                |                          | (X10^-5mm²/s) |           | (X10^-5mm²/s) |           |
| Axillary Lymph Node Metastasis |                          |              |           |              |           |
| Negative (-)                   | 21 (47.7%)               | 0.58-1.90/0.99±0.27/1.00 | *0.017*  | 0.51-1.60/0.83±0.22/0.81 | *0.019*  |
| 1-3 positive node (+)          | 10 (22.7%)               | 0.89-1.30/1.04±0.14/1.00 | *0.017*  | 0.68-1.00/0.87±0.11/0.87 | *0.019*  |
| 4-9 positive node (+)          | 9 (20.5%)                | 0.70-1.00/0.86±0.10/0.82 | *0.017*  | 0.62-0.88/0.72±0.10/0.72 | *0.019*  |
| >9 positive node (+)           | 4 (9.1%)                 | 0.80-0.90/0.84±0.05/0.83 | *0.017*  | 0.59-0.75/0.68±0.07/0.69 | *0.019*  |
| Histologic Grade              |                          |              |           |              |           |
| Grade 1                        | 7 (15.9%)                | 1.00         | *0.348    | 0.83         | *0.442    |
| Grade 2                        | 13 (29.5%)               | 0.90         | *0.348    | 0.75         | *0.442    |
| Grade 3                        | 24 (54.6%)               | 0.95         | *0.348    | 0.81         | *0.442    |
| Nuclear Grade                  |                          |              |           |              |           |
| Grade 1                        | 3 (6.8%)                 | 1.10         | *0.174    | 0.91         | *0.370    |
| Grade 2                        | 20 (45.5%)               | 0.90         | *0.174    | 0.78         | *0.370    |
| Grade 3                        | 24 (47.7%)               | 0.93         | *0.174    | 0.82         | *0.370    |
| Lymphovascular invasion        |                          |              |           |              |           |
| (+)                            | 21 (47.7%)               | 0.99         | *0.868    | 0.81         | *0.814    |
| (-)                            | 23 (52.3%)               | 0.90         | *0.868    | 0.80         | *0.814    |
| Estrogen Receptor(ER)          |                          |              |           |              |           |
| (+)                            | 39 (88.6%)               | 0.93         | *0.456    | 0.79         | *0.365    |
| (-)                            | 5 (11.4%)                | 0.90         | *0.456    | 0.82         | *0.365    |
| Progesterone Receptor(PR)      |                          |              |           |              |           |
| (+)                            | 30 (68.2%)               | 0.90         | *0.275    | 0.78         | *0.512    |
| (-)                            | 14 (31.8%)               | 1.00         | *0.275    | 0.82         | *0.512    |
| C-erbB-2 Protein               |                          |              |           |              |           |
| 0                              | 28 (63.7%)               | 0.98         | *0.710    | 0.80         | *0.291    |
| 1+                             | 4 (9.1%)                 | 1.00         | *0.710    | 0.85         | *0.291    |
| 2+                             | 2 (4.5%)                 | 0.91         | *0.710    | 0.63         | *0.291    |
| 3+                             | 10 (22.7%)               | 0.90         | *0.710    | 0.80         | *0.291    |
REFERENCES

1. Tuncbilek N, Karakas HM, Okten OO. Dynamic Magnetic Resonance Imaging in Determining Histopathological Prognostic Factors of Invasive Breast Cancers. Eur J Radiol. 2005 Feb;53(2):199-205.

2. Belli P, Costantini M, Bui E, Giardina GG, Rinaldi P, Franceschini G et al. Diffusion Magnetic Resonance Imaging in Breast Cancer Characterisation: Correlations Between the Apparent Diffusion Coefficient and Major Prognostic Factors. Radiol Med. 2015 Mar;120(3):268-76.

3. M C Segel, D D Paulus, G N Hortobagyi. Advanced Primary Breast Cancer: Assessment at Mammography of Response to Induction Chemotherapy. Radiology. 1988 Oct;169(1):49-54.

4. Kolb TM, Lichy J, Newhouse JH. Comparison of the Performance of Screening Mammography, Physical Examination, and Breast US and Evaluation of Factors That Influence Them: An Analysis of 27,825 Patient Evaluations. Radiology 2002 Oct;225(1):165-75.

5. Lee SH, Cho N, Kim SJ, Cha JH, Cho KS, Ko ES et al. Correlation Between High Resolution Dynamic MR Features and Prognostic Factors in Breast Cancer. Korean J Radiol. 2008 Jan-Feb;9(1):10-8. doi: 10.3348/kjr.2008.9.1.10.

6. Mussurakis S, Buckley DL, Horsman A. Dynamic MR Imaging of Invasive Breast Cancer: Correlation With Tumour Grade and Other Histological Factors. Br J Radiol. 1997 May;70(833):446-51.

7. Martinich L, Deantonio V, Bertotto I, Redana S, Kubatzki F, Sarotto I et al. Correlations Between Diffusion-Weighted Imaging and Breast Cancer Biomarkers. Eur Radiol. 2012 Jul;22(7):1519-28.

8. Pereira FP, Martins G, Carvalhaes de Oliveira Rde V. Diffusion Magnetic Resonance Imaging of the Breast. Magn Reson Imaging Clin N Am. 2011 Feb;19(1):95-110.

9. Razek AA, Gaballa G, Denewer A, Nada N. Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed. 2010 Jul;23(6):619-23.

10. Kamitani T, Matsuo Y, Yabuuchi H, Fujita N, Nagao M, Jinnouchi M et al. Correlations between apparent diffusion coefficient values and prognostic factors of breast cancer. Magn Reson Med Sci. 2013;12(3):193-9.

11. Choi SY, Chang YW, Park HJ, Kim HJ, Hong SS, Seo DY. Correlation of the apparent diffusion coefficient values on diffusion-weighted imaging with prognostic factors for breast cancer. Br J Radiol. 2012 Aug;85(1016):e474-9.

12. Woodhams R, Matsunaga K, Kan S, Hata H, Ozaki M, Iwabuchi K et al. ADC mapping of benign and malignant breast tumors. Magn Reson Med Sci. 2005 Aug ;4(1):35-42.

13. Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T et al. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med. 2008 May;26(4):222-6.

14. Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002 Aug;16(2):172-8.

15. Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH. The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol. 2007 Sep-Oct;8(5):390-6.

16. Hatakenaka M, Soeda H, Yabuuchi H, Matsuo Y, Kamitani T, Oda Y et al. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci. 2008 May;7(1):23-9.

17. Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi T et al. Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging. 2008 Nov;28(5):1157-65.

18. Woodhams R, Kakita S, Hata H, Iwabuchi K, Umeoka S, Mountford CE et al. Diffusion-weighted imaging of mucinous carcinoma of the breast: evaluation of apparent diffusion coefficient and signal intensity in correlation with histologic findings. AJR Am J Roentgenol. 2009 Jul;193(1):260-6.

19. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004 Mar;6(3):109-18.

20. Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Radiol 2014 February 1997;7(7):1002-5.

21. Cody DD, Mahesh M. AAPM/RSNA physics tutorial for residents: Technologic advances in multidetector CT with a focus on cardiac imaging. Radiographics. 2007 Nov-Dec;27(6):1829-37.

22. W A Kaiser. Dynamic Spiral MR Mammography.Radiology 2000 Jun;215(3):919-20.

23. Kim SH, Cha ES, Kim HS, Kang BJ, Choi JJ, Jung JH et al. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging. 2009 Sep;30(3):615-20.

24. Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9.
25. Kinoshita T, Yashiro N, Ihara N, Funatu H, Fukuma E, Narita M. Diffusion-weighted half-Fourier single-shot turbo spin echo imaging in breast tumors: differentiation of invasive ductal carcinoma from fibroadenoma. J Comput Assist Tomogr. 2002 Nov-Dec;26(6):1042-6.

26. Pereira FP, Martins G, Figueiredo E, Domingues MN, Domingues RC, da Fonseca LM et al. Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. AJR Am J Roentgenol. 2009 Oct;193(4):1030-5.

27. Pereira FP, Martins G, Figueiredo E, Domingues MN, Domingues RC, da Fonseca LM et al. Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. AJR Am J Roentgenol. 2009 Oct;193(4):1030-5.

28. Costantini M, Belli P, Rinaldi P, Bufi E, Giardina G, Franceschini G et al. Diffusion-weighted imaging in breast cancer: relationship between apparent diffusion coefficient and tumour aggressiveness. Clin Radiol. 2010 Dec;65(12):1005-12.

29. Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C. Quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesion. Eur Radiol. 2007 Oct;17(10):2646-55.

30. Buadu LD, Murakami J, Murayama S, Hashiguchi N, Sakai S, Masuda K et al. Breast lesions: correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis. Radiology. 1996 Sep;200(3):639-49.

31. Guo Y, Cai YQ, Cai ZL, Gao YG, An NY, Ma L et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002 Aug;16(2):172-8.

32. Partridge SC, Mullins CD, Kurland BF, Allain MD, DeMartini WB, Eby PR et al. Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol. 2010 Jun;194(6):1664-73.

33. Rubesova E, Grell AS, De Maertelaer V, Metens T, Chao SL, Lemort M. Quantitative diffusion imaging in breast cancer: a clinical prospective study. J Magn Reson Imaging. 2006 Aug;24(2):319-24.

34. Sinha S, Lucas-Quesada FA, Sinha U, DeBruhl N, Bassett LW. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging. 2002 Jun;15(6):693-704.

35. Yabuuchi H, Matsuo Y, Okafuji T, Kamitani T, Soeda H, Setoguchi et al. Enhanced mass on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging. 2008 Nov;28(5):1157-65.

36. Szabó BK, Aspelin P, Kristoffersen Wilberg M, Tot T, Boné B. Invasive breast cancer: correlation of dynamic MR features with prognostic factors. Eur Radiol. 2003 Nov;13(11):2425-35.

37. Montemurro F, Martincich L, Sarotto I, Bertotto I, Ponzzone R, Cellini L et al. Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. Eur Radiol. 2007 Jun;17(6):1490-7.

38. Narisada H, Aoki T, Sasaguri T, Hashimoto H, Konishi T, Morita M et al. Correlation between numeric gadolinium-enhanced dynamic MRI ratios and prognostic factors and histologic type of breast carcinoma. AJR Am J Roentgenol. 2006 Aug;187(2):297-306.

39. Iacconi C. Diffusion and perfusion of the breast. Eur J Radiol. 2010 Dec;76(3):386-90.